Inactive Instrument

Mylan N.V. Nasdaq

MYL

NL0011031208

Mylan : Denmark's Novo Nordisk files lawsuit against Mylan over patent

August 22, 2019 at 03:09 am EDT

COPENHAGEN (Reuters) - Novo Nordisk said on Thursday it has filed litigation in a Delaware district court against Mylan aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.

"We can confirm that Novo Nordisk has filed a lawsuit against Mylan for patent infringement of Victoza," the company said in an e-mail.

The news was first reported by Bloomberg.

(Reporting by Andreas Mortensen; editing by Jason Neely)

Latest news about Mylan N.V.

Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	Apr. 18	MT
UK Regulator to Consider Undertakings for Theramex-Viatris Deal	Apr. 18	MT
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada	Apr. 15	MT
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer	Apr. 15	CI
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada	Apr. 15	CI
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	Apr. 14	MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11	CI
UK's Theramex sees no impact to HRT products supply after CMA probe	Apr. 05	RE
UK Regulator Finds Competition Concerns in Theramex-Viatris Merger Deal	Apr. 04	MT
UK watchdog says Theramex-Viatris deal raises competition concerns	Apr. 04	RE
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent	Apr. 01	RE
Viatris Launches of Ryzumvi Eye Drops to Reverse Dilation in US	Apr. 01	MT
Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States	Apr. 01	CI
Viatris Seeks M&A	Mar. 27	CI
Transcript : Viatris Inc. - Special Call	Mar. 27
Stonex Group Insider Sold Shares Worth $488,142, According to a Recent SEC Filing	Mar. 25	MT
Pharmaceutical Groups Idorsia, Viatris Finalize Collaboration to Develop Selatogrel, Cenerimod	Mar. 18	MT
Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc..	Mar. 11	CI
Global markets live: 3M Company, Bayer, Apple, Boeing, Nvidia...	Mar. 11
Are good times already over?	Mar. 11
Viatris Says Mapi Pharma Receives FDA Complete Response Letter on Potential Multiple Sclerosis Drug	Mar. 11	MT
US FDA declines to approve Viatris's injection for multiple sclerosis	Mar. 11	RE
Viatris Insider Sold Shares Worth $1,005,609, According to a Recent SEC Filing	Mar. 06	MT

Chart Mylan N.V.

Duration

Period

More charts

Company Profile

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Companyâs ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.69%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-6.54%	351B
MERCK & CO., INC.	+14.84%	317B
ABBVIE INC.	+6.67%	292B
ASTRAZENECA PLC	+3.21%	211B
NOVARTIS AG	+0.53%	203B
PFIZER, INC.	-10.49%	144B
AMGEN INC.	-7.98%	141B

Other Pharmaceuticals